eFFECTOR
is a California-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer... Read moreeFFECTOR
is a California-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer... Read more
President & CEO
Craig R. Jalbert
News
Jun 26, 2024
MarketScreener
eFFECTOR: EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K
Jun 25, 2024
SFGate
eFFECTOR: Calif. biotech company that raised $325 million shuts down, lays off every remaining worker
Jun 24, 2024
Nasdaq
eFFECTOR: EFFECTOR To Wind Down Operations; Expects Securities To Be Delisted
May 20, 2024
BioSpace
eFFECTOR: eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer
May 10, 2024
Markets Insider
eFFECTOR: eFFECTOR Therapeutics GAAP EPS of -$2.16 beats by $0.01 (NASDAQ:EFTR)
May 09, 2024
GlobeNewswire
Press Release: eFFECTOR : eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 09, 2024
centralcharts
Press Release: eFFECTOR : eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
Apr 05, 2024
Zacks
eFFECTOR: eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
Apr 04, 2024
Benzinga
eFFECTOR: Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
Apr 04, 2024
GlobeNewswire
eFFECTOR: eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
eFFECTOR Competitors
1
2
3
4
5
6
7
8
9
10